Company Filing History:
Years Active: 2024
Title: Innovations of Julien Hasler in Selective Binding Compounds
Introduction
Julien Hasler is an accomplished inventor based in Hoogstraten, Belgium. He has made significant contributions to the field of biomedical research, particularly in the development of selective binding compounds that interact with the transferrin receptor (TfR). His innovative work has the potential to revolutionize the delivery of biomolecules across biological membranes.
Latest Patents
Julien Hasler holds a patent for his invention titled "TfR selective binding compounds and related methods." This patent describes peptides that bind with high specificity to the transferrin receptor, enabling the creation of molecular vehicles that can transport biomolecules across membranes, including the blood-brain barrier and the gastrointestinal tract. The invention focuses on VNAR single-chain antibodies derived from nurse sharks, which can be utilized in diagnostic and therapeutic applications to treat various pathological conditions.
Career Highlights
Julien Hasler is currently associated with Ossianix, Inc., where he continues to advance his research in the field of selective binding compounds. His work is pivotal in developing methods that can enhance the delivery of therapeutic agents, particularly in treating cancer cells and tumors.
Collaborations
Julien Hasler collaborates with notable colleagues, including Julia Lynn Rutkowski and Krzysztof Bartlomiej Wicher. Their combined expertise contributes to the innovative research and development efforts at Ossianix, Inc.
Conclusion
Julien Hasler's contributions to the field of selective binding compounds highlight the importance of innovation in biomedical research. His work not only advances scientific understanding but also holds promise for future therapeutic applications.